Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin–arginine

Allesø, 2009, Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: amorphous naproxen–cimetidine mixtures prepared by mechanical activation, J. Controlled Release, 136, 45, 10.1016/j.jconrel.2009.01.027 Löbmann, 2013, Amino acids as co-amorphous stabilizers for poorly water soluble drugs – Part 1: preparation, stability and dissolution enhancement, Eur. J. Pharm. Biopharm., 85, 873, 10.1016/j.ejpb.2013.03.014 Löbmann, 2013, Amino acids as co-amorphous stabilizers for poorly water-soluble drugs – Part 2: molecular interactions, Eur. J. Pharm. Biopharm., 85, 882, 10.1016/j.ejpb.2013.03.026 Jensen, 2015, Preparation and characterization of spray dried co-amorphous drug-amino acid salts, J. Pharm. Pharmacol. Fell, 1970, Determination of tablet strength by the diametral-compression test, J. Pharm. Sci., 59, 688, 10.1002/jps.2600590523 European Pharmacopoeia 8.2, 2.9.1, Disintegration of Tablets and Capsules, European Pharmacopoeia Commission, European Directorate for the Quality of Medicines, Strasbourg, France, 2014, pp. 285–287. European Pharmacopoeia 8.2, 2.9.40, Uniformity of Dosage Units, European Pharmacopoeia Commission, European Directorate for the Quality of Medicines, Strasbourg, France, 2014, pp. 357–359. Kaneniwa, 1985, Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol, Chem. Pharm. Bull., 33, 3447, 10.1248/cpb.33.3447 European Pharmacopoeia 8.2, Mannitol, European Pharmacopoeia Commission, European Directorate for the Quality of Medicines, Strasbourg, France, 2014, pp. 4072–4073. Quodbach, 2014, Systematic classification of tablet disintegrants by water uptake and force development kinetics, J. Pharm. Pharmacol., 66, 1429, 10.1111/jphp.12276 Ayenew, 2012, Effect of compression on non-isothermal crystallization behaviour of amorphous indomethacin, Pharm. Res., 29, 2489, 10.1007/s11095-012-0778-5 Thakral, 2015, Compression-induced crystallization of amorphous indomethacin in tablets: characterization of spatial heterogeneity by two-dimensional X-ray diffractometry, Mol. Pharm., 12, 253, 10.1021/mp5005788 Amidon, 1995, A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413, 10.1023/A:1016212804288 O’Brien, 1984, Indomethacin, vol. 13, 211 Cavallari, 2005, Release of indomethacin from ultrasound dry granules containing lactose-based excipients, J. Controlled Release, 102, 39, 10.1016/j.jconrel.2004.09.017 Sheth, 2005, Mechanochromism of piroxicam accompanied by intermolecular proton transfer probed by spectroscopic methods and solid-phase changes, J. Am. Chem. Soc., 127, 6641, 10.1021/ja045823t Priemel, 2013, In situ amorphisation of indomethacin with Eudragit® E during dissolution, Eur. J. Pharm. Biopharm., 85, 1259, 10.1016/j.ejpb.2013.09.010 E. Lenz, K.T. Jensen, K. Löbmann, T. Rades, P. Kleinebudde, Tableting of spray dried co-amorphous indomethacin–arginine, AAPS Annual Meeting, San Diego, USA, 2014. Yamamoto, 1968, 1-Acyl-indoles. II. A new syntheses of 1-(p-chlorobenzoyl)-5-methoxy-3-indolylacetic acid and its polymorphism, Chem. Pharm. Bull., 16, 17, 10.1248/cpb.16.17 Borka, 1974, The polymorphism of indomethacine. New modifications, their melting behavior and solubility, Acta Pharm. Suec., 11, 295 Lin, 1992, Isolation and solid-state characteristics of a new crystal form of indomethacin, J. Pharm. Sci., 81, 572, 10.1002/jps.2600810622 Surwase, 2013, Indomethacin: new polymorphs of an old drug, Mol. Pharm., 10, 4472, 10.1021/mp400299a Aubrey-Medendorp, 2008, The polymorphism of indomethacin: an analysis by density functional theory calculations, Pharm. Res., 25, 953, 10.1007/s11095-007-9346-9 V. Joshi, Physical Transformations in Solvated Pharmaceuticals, PhD Thesis, Purdue University, West Lafayette, USA, 1998. Hamdi, 2004, Solvates of indomethacin, J. Therm. Anal. Calorim., 76, 985, 10.1023/B:JTAN.0000032284.89029.06 J.A. Ryan, Crystalline Sodium and Potassium Indomethacin and their Trihydrates, Process for Preparing and Pharmaceutical Compositions Containing the Same, EP Patent 0006223A1 (1980). Dubbini, 2014, Influence of pH and method of crystallization on the solid physical form of indomethacin, Int. J. Pharm., 473, 536, 10.1016/j.ijpharm.2014.07.030 Savolainen, 2007, Screening for differences in the amorphous state of indomethacin using multivariate visualization, Eur. J. Pharm. Sci., 30, 113, 10.1016/j.ejps.2006.10.010 Andronis, 1997, Effects of sorbed water on the crystallization of indomethacin from the amorphous state, J. Pharm. Sci., 86, 346, 10.1021/js9602711 Andronis, 2000, Crystal nucleation and growth of indomethacin polymorphs from the amorphous state, J. Non-Cryst. Solids, 271, 236, 10.1016/S0022-3093(00)00107-1 Rumondor, 2009, Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture, Mol. Pharm., 6, 1492, 10.1021/mp900050c